Seth Robey

Seth Robey

PharmTeam

Lab scientist by day. Motley Fool Contributor by night. Fusing a love for science and money into new biotech investment ideas. Follow @SethRobey on twitter.

Recent articles





Is It Time to Buy Eli Lilly & Co.'s Stock?

Eli Lilly & Co. is promising big things, but has optimism in the stock gotten ahead of reality? It's time to ask if now's the right time to invest.


3 Reasons Eli Lilly & Co.'s Stock Could Fall

Management at Eli Lilly & Co. has faced a mountain of challenges in the wake of debilitating patent losses, but the stock has held strong regardless. Here are three reasons that rally may not continue into the future.





Are Cancer Vaccines Worth an Investment?

Immuno-oncology has been the darling of biotech investors, but growth in one segment of the industry might not look as strong as you think.


Why Are Companion Diagnostics So Important?

Patients, doctors, and investors have been excited about new frontiers in oncology, but can these drugs be useful without companion diagnostics?


Is Apple Disrupting Health Care's Disruptors?

With its new operating system and health app interface, Apple will enable doctors to play more of a role in patient-focused care. How will that change the landscape of health care IT providers?


ASCO Showdown: AstraZeneca vs. Clovis Oncology

The annual meeting brings together some of the world's most exciting emerging cancer treatments, and after only a day AztraZenica and Clovis are making waves as the compete in the lung cancer market.


3 Biotechs Worthy of a Stanley Cup

If these three drug makers were hockey teams, you can bet they'd have what it takes to compete at hockey's highest level.


3 Questions About a Big Pharma Megamerger

From pipelines to competitive landscapes, here are three questions that could shape a huge acquisition and the markets they operate in.